email article
Transitioning high-sensitivity troponin testing protocols in the emergency department for suspected acute coronary syndrome can have some unintended consequences, studies showed.
In a prospective multicenter trial from Australia, patients randomized to a 0/1-hour high-sensitivity cardiac troponin-T (hs-cTnT) protocol unmasked to the care team had similar all-cause mortality and MI at 12 months as those whose early levels were masked and were treated based on the standard protocol of 0/3-hour testing (5.0% vs 3.8%, HR 1.32, 95% CI 0.95-1.83).
However, for those with an intermediate elevation in troponin of less than 29 ng/L the only group for whom results differed between the two trial arms, with reporting to
Rivaroxaban Reduces First and Total Ischemic Events in Patients with Peripheral Artery Disease dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.
iStock
May 14, 2021
Your heart valves are the small but mighty heroes of your circulatory system these four paper-thin membranes attached to the heart wall do a ton of work to keep your heart beating (and you, alive). In fact, they open and close a whopping 80 million times a year! So, keeping them strong and free of problems, like stenosis (when the valves thicken or stiffen) and regurgitation (when blood sneaks back through it the wrong direction) is crucial. How do you do that? With these smart lifestyle, diet, and health moves that will keep those little babies flapping with more ease.
E-Mail
Patients with chronic kidney disease and Type 2 diabetes who took the experimental drug finerenone were about 30% less likely to develop the heart rhythm disorder atrial fibrillation (AFib) than those taking a placebo, according to data presented at the American College of Cardiology s 70th Annual Scientific Session.
Last year, researchers reported that the trial, called FIDELIO-DKD, met its primary endpoint showing a significant benefit of finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, in terms of a composite of sustained decrease in kidney function, kidney failure and renal death. The new analysis reveals that patients derived these benefits regardless of their history with AFib and suggests that taking finerenone also reduced the rate of new-onset AFib.